Clinical Trial Update: Evaluation of RC28-E Injection in Wet Age-related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 trial evaluating RC28-E injection for wet age-related macular degeneration has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• RC28-E

Snippet

Sponsor: RemeGen Co., Ltd. | Conditions: Wet Age-Related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED